ETF Holdings Breakdown of VRDN

News associated with VRDN

Rhumbline Advisers Buys 4,621 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Rhumbline Advisers lifted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 4.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 104,559 shares of the company’s stock after acquiring an additional 4,621 shares during the quarter. Rhumbline Advisers’ […] - 2025-06-19 07:10:54

Squarepoint Ops LLC Lowers Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Squarepoint Ops LLC reduced its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 23.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,251 shares of the company’s stock after selling 10,328 shares during the quarter. Squarepoint Ops LLC’s holdings in […] - 2025-06-04 08:06:50

Nuveen Asset Management LLC Has $13.06 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Nuveen Asset Management LLC boosted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 198.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 681,012 shares of the company’s stock after acquiring an additional 452,627 shares during the quarter. Nuveen Asset […] - 2025-05-27 09:05:03

Viridian Announces Positive Long-Term Data From Phase 3 Trial Of Veligrotug In Thyroid Eye Disease

(RTTNews) - Viridian Therapeutics Inc. (VRDN) announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug or "veli", an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye - 2025-05-20 11:29:45

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Position Increased by Barclays PLC

Barclays PLC lifted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 25.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 157,860 shares of the company’s stock after buying an additional 32,463 shares during the quarter. Barclays PLC’s holdings in Viridian Therapeutics were worth $3,027,000 at the end of the […] - 2025-04-30 08:50:47

Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts […] - 2025-04-28 06:08:56

Geode Capital Management LLC Purchases 165,669 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Geode Capital Management LLC increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 11.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,658,980 shares of the company’s stock after acquiring an additional 165,669 shares […] - 2025-04-17 07:52:50

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Holdings Lifted by Corebridge Financial Inc.

Corebridge Financial Inc. grew its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 8.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,336 shares of the company’s stock after buying an additional 2,878 shares during […] - 2025-04-07 07:32:49

Comparing Viridian Therapeutics (NASDAQ:VRDN) & ACI Global (OTCMKTS:ACGJ)

ACI Global (OTCMKTS:ACGJ – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both industrials companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk. Profitability This table compares ACI Global and Viridian […] - 2025-04-03 06:08:55

Swiss National Bank Boosts Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Swiss National Bank grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 4.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 112,600 shares of the company’s stock after buying an additional 4,500 shares during the quarter. Swiss National Bank’s holdings in Viridian Therapeutics were worth $2,159,000 at the end of the […] - 2025-03-28 07:52:52

Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Target Price at $35.70

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The […] - 2025-02-26 06:23:00

R Squared Ltd Takes $26,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

R Squared Ltd acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,340 shares of the company’s stock, valued at approximately $26,000. A number of other hedge funds have also […] - 2025-02-05 08:42:52

VRDN institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	35,288	USD 513,440
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	71,571	USD 1,041,358
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	3,991	USD 58,069
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	101,925	USD 1,483,009
Total =		212,775	USD 3,095,876

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer